Exparel Application Under Review for Sciatic and Femoral Nerve Blocks
The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Exparel (bupivacaine liposome injectable suspension) to include both single-dose sciatic nerve block in the popliteal fossa as well as femoral nerve block in the adductor canal.
Comment
expand_more
expand_less